Elwell, Valerie From: UCI Health <[email protected]> Sent: Tuesday, August 17, 2021 7:00 AM To: Elwell, Valerie Subject: Cancer Clinical Trials These featured cancer clinical trials are currently open at the UCI Health Chao Family Comprehensive Cancer Center. To refer a patient or get more information about a clinical trial, click on the principal investigator’s name to send an email. You may also contact us at [email protected] or 877-UC-Study. To search all cancer clinical trials now available at UCI Health, visit cancer.uci.edu/clinical-trials-flowcharts Brain and nervous system A phase 2 study of the PARP inhibitor olaparib (AZD2281) in IDH1 and IDH2 mutant, advanced solid tumors (ETCTN-10129) Principal investigator: Xiao-Tang Kong, MD A phase 3, randomized, double-blind, placebo-controlled study of enzastaurin added to temozolomide during and following radiation therapy in newly diagnosed glioblastoma patients who possess the novel genomic biomarker DGM1 (UCI 19-99/DB102-01) Principal investigator: Daniela Bota, MD Breast A phase 2 trial of radium-223 dichloride in combination with paclitaxel in patients with metastatic breast cancer that has spread to the bones (ETCTN-10302) Principal investigator: Ritesh Parajuli, MD A phase 3, randomized, double-blind study of tucatinib or placebo in combination with 1 ado-trastuzumab emtansine (T-DM1) for subjects with unresectable, locally advanced or metastatic HER2+ breast cancer (UCI 19-66/SGNTUC-016) Principal investigator: Ritesh Parajuli, MD COVID-19 NCI COVID-19 in Cancer Patients Study (NCCAPS): a longitudinal natural history study (NCICOVID) Principal investigator: Hannah Hyochan Nam, MD Gastrointestinal A phase 2, randomized study of trastuzumab and pertuzumab (TP) compared to cetuximab and irinotecan (CETIRI) in HER2 amplified, irinotecan-refractory metastatic colorectal cancer (mCRC) (S1613) Principal investigator: Farshid Dayyani, MD A phase 1 study of cabozantinib in combination with trifluridine/tipiracil (TAS-102) in patients with metastatic colorectal adenocarcinoma (mCRC) (UCI 20-134) Principal investigator: Farshid Dayyani, MD Genitourinary A phase 2, single-arm study of CG0070 combined with pembrolizumab in patients with non-muscle invasive bladder cancer (NMIBC), unresponsive to bacillus Calmette-Guérin (BCG) (UCI 20-91/CG2003C) Principal investigator: Edward Uchio, MD A phase 3, open-label, randomized, controlled study of enfortumab vedotin in combination with pembrolizumab vs. chemotherapy alone in previously untreated, locally advanced or metastatic urothelial cancer (UCI 19-143/SGN22E-003, EV-302) Principal investigator: Nataliya Mar, MD A phase 1/2, open-label, dose-escalation and cohort-expansion clinical trial to evaluate the safety, tolerability, pharmacokinetics and pharmacodynamics of ARV-110 in patients with metastatic, castration-resistant prostate cancer (UCI 20-138/ARV-110-mCRPC-101) Principal investigator: Arash Rezazadeh Kalebasty, MD Gynecologic oncology 2 A phase 2/3, randomized study of pegylated liposomal doxorubicin and CTEP-supplied atezolizumab vs. pegylated liposomal doxorubicin/bevacizumab and CTEP-supplied atezolizumab vs. pegylated liposomal doxorubicin/bevacizumab in platinum-resistant ovarian cancer (NRG-GY009) Principal investigator: Krishnansu Tewari, MD A phase 1b, first-in-human, dose-escalation and expansion study of XMT-1536 in patients with solid tumors likely to express NaPi2b (GOG-3048/MER-XMT-1536-1) Principal investigator: Jill Tseng, MD Head and neck Randomized phase 2 and phase 3 studies of individualized treatment for nasopharyngeal carcinoma based on biomarker Epstein-Barr virus (EBV) deoxyribonucleic acid (DNA) (NRG-HN001) Principal investigator: Rupali Nabar, MD A randomized phase 2/3 trial of adjuvant radiation therapy with cisplatin, docetaxel- cetuximab or cisplatin-atezolizumab in pathologic, high-risk, squamous cell cancer of the head and neck (RTOG-1216) Principal investigator: Rupali Nabar, MD Hematologic malignancies The PRIME Trial: PARP inhibition in IDH mutant effectiveness trial. A phase 2 study of olaparib in isocitrate dehydrogenase (IDH) mutant relapsed/refractory acute myeloid leukemia and myelodysplastic syndrome (ETCTN-10264) Principal investigator: Deepa Jeyakumar, MD A phase 2 study of CPX-351 combined with glasdegib in previously untreated patients with acute myelogenous leukemia with MDS-related changes or therapy-related acute myeloid leukemia (UCI 18-105/WI242625/UCHMC1913) Principal investigator: Deepa Jeyakumar, MD Hepatobiliary A phase 1/2 study of M3814 (peposertib) in combination with hypofractionated radiotherapy to treat locally advanced pancreatic adenocarcinoma (ETCTN-10366) Principal investigator: Farshid Dayyani, MD 3 A phase 2 study of cabozantinib combined with ipilimumab/nivolumab and transarterial chemoembolization (TACE) in patients with hepatocellular carcinoma (HCC) who are not candidates for curative intent treatment (UCI 19-49) Principal investigator: Farshid Dayyani, MD Lung A phase 2 study to evaluate the safety and efficacy of AB122 monotherapy, AB154 in combination with AB122, and AB154 in combination with AB122 and AB928 in frontline, non-small cell lung cancer (UCI 20-107/AB154CSP0002 (ARC-7)) Principal investigator: Sai-Hong Ou, MD A phase 1, open-label, multicenter, dose-escalation and dose-expansion study to evaluate the safety, tolerability, pharmacokinetics and preliminary evidence of anti-tumor activity of PF-07284892 (ARRY-558) as a single agent and in combination therapy in participants with advanced solid tumors (UCI 20-211/C4481001) Principal investigator: Sai-Hong Ou, MD Skin A phase 2 study of talimogene laherparepvec (T-VEC) and radiation in localized soft tissue sarcoma (ETCTN-10056) Principal investigator: Jeremy Phillip Harris, MD A phase 1/2 study of dabrafenib, trametinib and navitoclax in BRAF-mutant melanoma (phase 1 and 2) and other solid tumors (phase 1 only) (ETCTN-9466) Principal investigator: Jennifer Valerin, MD UCI Medical Center | 101 The City Drive South | Orange, CA 92868 4 08/21 5.